Sanofi snags bigger stake, new pact with Regeneron

Regeneron is feeling the warm embrace of Sanofi-Aventis, France's acquisition-hungry pharma giant. Sanofi has upped its stake in Regeneron from 4 percent to 19 percent while putting up $85 million in an up-front fee to seal a development deal covering therapeutic antibodies. Regeneron could gain up to $475 million over the next five years, and there's an option to extend the deal by another three years.

This deal is packed with all sorts of provisions. According to the wire services, Sanofi--which has signaled that it is still in the hunt for a new biotech acquisition--has an option to up its stake in Regeneron to 30 percent. Regeneron gets a split on profits from any successful therapies approved in the U.S. with a smaller stake for the rest of the world. There's also $250 million in sales milestones after international revenue tops a billion dollars. First target for the collaboration: Rheumatoid arthritis.

- see this release
- read the AP report on the deal

Suggested Articles

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.

Broad Institute researchers showed that base-editing the Tmc1 gene preserved hair cells that helped transmit sound in the ears of mice.